Vai offline con l'app Player FM !
Highlights in gynecologic cancer from ESMO 2023
Manage episode 385528189 series 2424442
The European Society for Medical Oncology (ESMO) Congress 2023 gathered prominent experts to discuss the latest research and breakthroughs in oncology. In this podcast, joining us will be Mary McCormack (UCL Hospitals NHS Foundation Trust, London, UK), Benoit You (Lyon University Hospital, Lyon, France), Domenica Lorusso (Fondazione IRCCS National Cancer Institute of Milan, Italy), Mansoor Raza Mizra (Copenhagen University Hospital, Denmark) and Shannon N. Westin (MD Anderson Cancer Center, Houston, TX).
Updates from multiple trials are discussed, highlighting the efficacy of induction chemotherapy plus chemoradiation in the INTERLACE trial, the combination of pembrolizumab with chemoradiation in the KEYNOTE-A18 trial (NCT04221945), and the potential of tisotumab vedotin in the innovaTV 301 trial (NCT04697628)—all focusing on advanced cervical cancer. Additionally, discussions cover the RUBY (NCT03981796) and DUO-E (NCT04269200) trials exploring the use of various immunotherapy agents combined with chemotherapy for the treatment of advanced endometrial cancer.
The post Highlights in gynecologic cancer from ESMO 2023 appeared first on VJOncology.
174 episodi
Manage episode 385528189 series 2424442
The European Society for Medical Oncology (ESMO) Congress 2023 gathered prominent experts to discuss the latest research and breakthroughs in oncology. In this podcast, joining us will be Mary McCormack (UCL Hospitals NHS Foundation Trust, London, UK), Benoit You (Lyon University Hospital, Lyon, France), Domenica Lorusso (Fondazione IRCCS National Cancer Institute of Milan, Italy), Mansoor Raza Mizra (Copenhagen University Hospital, Denmark) and Shannon N. Westin (MD Anderson Cancer Center, Houston, TX).
Updates from multiple trials are discussed, highlighting the efficacy of induction chemotherapy plus chemoradiation in the INTERLACE trial, the combination of pembrolizumab with chemoradiation in the KEYNOTE-A18 trial (NCT04221945), and the potential of tisotumab vedotin in the innovaTV 301 trial (NCT04697628)—all focusing on advanced cervical cancer. Additionally, discussions cover the RUBY (NCT03981796) and DUO-E (NCT04269200) trials exploring the use of various immunotherapy agents combined with chemotherapy for the treatment of advanced endometrial cancer.
The post Highlights in gynecologic cancer from ESMO 2023 appeared first on VJOncology.
174 episodi
Tutti gli episodi
×Benvenuto su Player FM!
Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.